JPRN-UMIN000010440已完成未知
Multicenter Pivotal Clinical Study of TRM-1106 (Phase III) - Pivotal Clinical Study of TRM-1106
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •For the following criteria (1) to (9), the investigator or sub-investigator will determine whether the patient is to be excluded based on the reference. <before surgery> (1) Patients resistant to opioids. (2) Patients with a history of alcohol addiction or drug abuse within the past 1 year. (3) Patients with hepatic dysfunction. Reference: ALT or AST is more than double the upper limit of the site, and total bilirubin or prothrombin time is more than double the upper limit of the site. (4) Patients with hepatic disease (hepatic cirrhosis or hepatitis) and whose ALT or AST is more than double the upper limit of the site or who are determined to have an increased risk of hepatotoxicity after administration of the study drug. (5) Patients with a past history of hypersensitivity or allergy to any of the ingredients of the study drug, or patients who experienced no therapeutic effects for acetaminophen in the past. (6) Patients who have peptic ulcer or a past history of peptic ulcer, or patients who have asthma or a past history of asthma. (7) Patients with a serious blood disorder, renal disorder, or cardiac dysfunction. (8) Patients who have aspirin-induced asthma or a past history of aspirin-induced asthma. (9) Hypertensive patients resistant to drug therapy. Reference: Systolic blood pressure 160 mm Hg or above or diastolic blood pressure 100 mm Hg or above. (10) Pregnant or lactating women. (11) Patients who participated in other clinical study within 6 months before the start of this study. (12) Patients who are determined by the investigator or sub-investigator to be ineligible for participation in this study. <after surgery before the first administration of the study drug> (13) Patients treated with any of the prohibited concomitant drugs specified in this protocol. (14) Patients who need be treated with an antipyretic. (15) Patients who are scheduled or expected to receive other surgery during the study period.
研究者
相似试验
已完成
不适用
Multicenter General Clinical Study of TRM-1106 (Phase III)The subjects will be patients with postoperative pain.JPRN-UMIN000010403Terumo Corporation80
已完成
不适用
Multicenter Study of TCD-11091 (Phase III Clinical Study)Patients with primary rectal cancer who are scheduled to undergo loop ileostomy during laparotomyJPRN-UMIN000010356Terumo Corporation124
未知
不适用
A prospective multicenter registry study of the treatment in patient with Japanese CLIperipheral artery diseaseJPRN-UMIN000001269Shonan Kamakura General Hospital200
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2 positive metastatic breast cancerMedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001628-37-EEF. Hoffmann-La Roche Ltd2,003
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.EUCTR2012-001628-37-FIF. Hoffmann-La Roche Ltd2,003